30-Second Takeaway
- Tucidinostat plus R-CHOP improves event-free survival and complete response rates in MYC/BCL2 double-expressor DLBCL with acceptable toxicity.
- Early BCMA CAR-T in high-risk smoldering myeloma yields universal deep MRD negativity with manageable, mostly low-grade toxicities.
- Asciminib delivers durable molecular responses after ≥2 TKIs in CML-CP, reinforcing its role as preferred salvage TKI.
Week ending April 25, 2026
Targeted and Cellular Strategies Shift Risk-Adapted Care Across Hematologic Malignancies
Tucidinostat plus R-CHOP improves frontline outcomes in MYC/BCL2 double-expressor DLBCL
In newly diagnosed MYC/BCL2 double-expressor DLBCL, adding tucidinostat to R-CHOP reduced event risk by 28% versus R-CHOP alone. Two-year event-free survival was 60.3% with tucidinostat plus R-CHOP versus 50.5% with R-CHOP alone. Complete response rates improved from 61.8% with R-CHOP to 73.0% with tucidinostat plus R-CHOP. Toxicity increased but was generally manageable with supportive measures, without prohibitive safety signals.
Cilta-cel induces universal deep MRD negativity in high-risk smoldering myeloma
In CAR-PRISM, 20 high-risk smoldering myeloma patients received single-infusion ciltacabtagene autoleucel without induction or bridging therapy. At median 15.3 months follow-up, all patients achieved and maintained MRD negativity at 10^-6 within 2 months. Among 16 patients with >6 months follow-up, all achieved complete responses, with no progression or deaths observed. Toxicities included universal grade 1–2 cytokine release syndrome, frequent transient grade 3/4 cytopenias, and mostly reversible neurologic events without dose-limiting toxicities.
FLAG-Ida delivers substantial remission and transplant access in first R/R AML
In 1079 adults with first relapsed or refractory AML, FLAG-Ida achieved a composite complete remission rate of 56.8%. Overall, 35.2% of patients, representing 62% of responders, proceeded to allogeneic transplantation in morphologic remission. Median overall survival was 10.2 months, with a 5-year overall survival of 21.6%. Older age, modified high-risk cytogenetics, and FLT3-ITD predicted worse survival, while prior transplant and relapse-free interval ≥1 year were favorable.
ASC4OPT supports asciminib as go-to option after ≥2 TKIs in CML-CP
ASC4OPT enrolled 169 CML-CP patients with ≥2 prior TKIs and unsatisfactory responses by ELN 2020 criteria. Among patients not in major molecular response at baseline, asciminib achieved 39.4% major molecular response at Week 48 and 43.6% at Week 96. Efficacy was similar between 40 mg twice daily and 80 mg once daily dosing, with limited benefit from dose escalation. Most patients already in major molecular response at baseline maintained responses through 96 weeks.
References
Numbered in order of appearance. Click any reference to view details.
Additional Reads
Optional additional studies from this edition.